Clinical Trials Browser

Completed × Insulin-Like Growth Factor I, Resistance To × Clear all

NCT00889382 2024-11-20

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Phase 1/2 Completed

152 enrolled

Gynecologic

Insulin-Like Growth Factor I, Resistance To, Ovarian Neoplasms

NCT00924989 2024-11-20

GALACCTIC

Phase 3 Completed

139 enrolled

Endocrine

Insulin-Like Growth Factor I, Resistance To, Adrenocortical Carcinoma

NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Phase 1/2 Completed

138 enrolled 19 charts

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

NCT04767750 2022-04-07

Role of LncRNA H19 in The Regulation of IGF-1R Expression

Completed

101 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Neoplasms

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT00563680 2016-10-27

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

Phase 2 Completed

38 enrolled

Sarcoma

Askin Tumor, Insulin-Like Growth Factor I, Resistance To, Sarcoma, Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

NCT01733004 2016-08-04

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

Phase 1 Completed

42 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Neoplasms

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

27 enrolled

Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT00956436 2013-09-16

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Phase 1 Completed

40 enrolled

Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Hepatocellular, Liver Neoplasms